Showing results (21-30 of 118) with videos related to
Sort By:
Pageof 12
Current Treatment Options in Oncology|August 31, 2013
Bevacizumab in advanced NSCLC: chemotherapy partners and duration of useRyan D Gentzler, Sarah E Yentz, Jyoti D PatelBiorxiv : the Preprint Server for Biology|April 10, 2023
Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancerIgor Bychkov, Iuliia Topchu, Petr Makhov, et al.Cancers|May 13, 2023
Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung CancerIgor Bychkov, Iuliia Topchu, Petr Makhov, et al.Archives of Pathology & Laboratory Medicine|April 3, 2013
Molecular profiling in non-small cell lung cancer: a step toward personalized medicineKirtee Raparia, Celina Villa, Malcolm M DeCamp, et al.Frontiers in Oncology|November 16, 2020
Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase InhibitorsKaram Khaddour, Sandra L Gomez-Perez, Nikita Jain, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Role of American Society of Clinical Oncology in low- and middle-income countriesJyoti D Patel, Matthew D Galsky, Anees B Chagpar, et al.Clinical Lung Cancer|August 30, 2025
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung CancerChetan V Vakkalagadda, Leslie Bucheit, Keelia Clemens, et al.Current Problems in Cancer|May 8, 2025
Dosing immune-checkpoint inhibitors: Opportunities for the futureWon Jin Jeon, So Young Son, Faith Abodunrin, et al.Cancer|August 27, 2014
The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteriaRyan D Gentzler, Sarah E Yentz, Melissa L Johnson, et al.Seminars in Oncology|March 14, 2003
Targeting lethal minimal residual disease in small cell lung cancerJyoti D Patel, Lee M Krug, Christopher G Azzoli, et al.Pageof 12